WO2010039510A3 - Use of syndyphalin-33 (sd-33; try-dmet(o)-gly-methylphenylethylamide) as a therapeutic agent to enhance the health and well-being of newly-weaned animals - Google Patents

Use of syndyphalin-33 (sd-33; try-dmet(o)-gly-methylphenylethylamide) as a therapeutic agent to enhance the health and well-being of newly-weaned animals Download PDF

Info

Publication number
WO2010039510A3
WO2010039510A3 PCT/US2009/057950 US2009057950W WO2010039510A3 WO 2010039510 A3 WO2010039510 A3 WO 2010039510A3 US 2009057950 W US2009057950 W US 2009057950W WO 2010039510 A3 WO2010039510 A3 WO 2010039510A3
Authority
WO
WIPO (PCT)
Prior art keywords
animals
syndyphalin
methylphenylethylamide
dmet
gly
Prior art date
Application number
PCT/US2009/057950
Other languages
French (fr)
Other versions
WO2010039510A2 (en
Inventor
Cheryl J. Kojima
Original Assignee
University Of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Tennessee Research Foundation filed Critical University Of Tennessee Research Foundation
Publication of WO2010039510A2 publication Critical patent/WO2010039510A2/en
Publication of WO2010039510A3 publication Critical patent/WO2010039510A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The subject invention provides for the administration of syndyphalin-33 (SD33; Tyr- DMet (o)-Gly-methylphenylethylamide), or compositions thereof, to animals for the management of stress response (e.g., shipping fever in cattle or cachexia and/adaptation/stress management in companion or exotic animals) within the animals. The subject invention also provides methods of improving young animal survival comprising the administration of SD33 to young animals prior to weaning. Another aspect of the invention provides methods of increasing the numbers of immune effector cells in an animal comprising the administration of SD33 to young animals. Additional aspects of the invention also include methods of reducing the severity of enteric infections in young animals.
PCT/US2009/057950 2008-09-23 2009-09-23 Use of syndyphalin-33 (sd-33; try-dmet(o)-gly-methylphenylethylamide) as a therapeutic agent to enhance the health and well-being of newly-weaned animals WO2010039510A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9922808P 2008-09-23 2008-09-23
US61/099,228 2008-09-23

Publications (2)

Publication Number Publication Date
WO2010039510A2 WO2010039510A2 (en) 2010-04-08
WO2010039510A3 true WO2010039510A3 (en) 2010-07-08

Family

ID=42074105

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/057950 WO2010039510A2 (en) 2008-09-23 2009-09-23 Use of syndyphalin-33 (sd-33; try-dmet(o)-gly-methylphenylethylamide) as a therapeutic agent to enhance the health and well-being of newly-weaned animals

Country Status (1)

Country Link
WO (1) WO2010039510A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001516A1 (en) * 1984-09-04 1986-03-13 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US6235496B1 (en) * 1993-03-08 2001-05-22 Advanced Research & Technology Institute Nucleic acid encoding mammalian mu opioid receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001516A1 (en) * 1984-09-04 1986-03-13 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US6235496B1 (en) * 1993-03-08 2001-05-22 Advanced Research & Technology Institute Nucleic acid encoding mammalian mu opioid receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOJIMA, C.J. ET AL.: "Effects of syndyphalin-33 on feed intake and circulating measures of growth hormone, cortisol, and immune cell populations in the recently weaned pig", J. ANIM. SCI., vol. 87, no. 10, June 2009 (2009-06-01), pages 3218 - 3225 *
OBESE, F.Y. ET AL.: "Long-term feed intake regulation in sheep is mediated by opioid receptors", J ANIM SCI., vol. 85, no. 1, January 2007 (2007-01-01), pages 111 - 117 *

Also Published As

Publication number Publication date
WO2010039510A2 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
WO2008076915A3 (en) Treatment of pigs with pcv2 antigen
WO2012087742A3 (en) Methods and compositions suitable for managing blood glucose in animals
CR20110441A (en) PREPARATIONS FOR THE SYNCHRONICATION OF ESTRAL CYCLE AND EFFECTIVE PROTOCOLS.
WO2010059529A3 (en) Compositions comprising 1-arylpyrazole alone or in combination with formamidine for the treatment of parasitic infection
WO2007046834A3 (en) Glp-1 agonists, compositions, methods and uses
MD4577B1 (en) Chewable veterinary compositions comprising an isoxazoline active agent and their use in the treatment and/or prophylaxis of a parasitic infection and infestation
WO2008011446A3 (en) Human glp-1 mimetibodies, compositions, methods and uses
WO2008147483A3 (en) Neurogenic compounds
WO2007009701A3 (en) Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
WO2010133359A3 (en) The improvement of gastrointestinal health, immunity and performance by dietary intervention
WO2007150008A3 (en) Polypeptides from african swine virus as vaccines for preventive and therapeutic use
EP2418961A4 (en) Milk oligosaccharide compositions and use thereof in treating infection in animals
WO2008040550A3 (en) Olive extracts for promoting muscle health
WO2009038090A1 (en) Composition comprising sesamin component and arachidonic acid component
ZA200905126B (en) Use of compounds of formula (i) and/or (II) for the preservation of human or animal bodies, and compositions containing the same
WO2010039510A3 (en) Use of syndyphalin-33 (sd-33; try-dmet(o)-gly-methylphenylethylamide) as a therapeutic agent to enhance the health and well-being of newly-weaned animals
WO2012009542A3 (en) Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration
CL2009000987A1 (en) Feed composition comprising peptidoglycan and nucleotides; and its use for the prophylaxis and / or treatment of infectious diseases in animals.
WO2009087286A3 (en) Use of a 1-n-(halo-3-pyridylmethyl)-n-methylamino-1-alkylamino-2-nitroethylene derivative for preparing a topical veterinary pharmaceutical composition for combating external parasites
WO2008075333A3 (en) Edible compositions for preventing hair loss
NO20075272L (en) Human GLP-1 "mimetibodies", compositions, methods and applications
WO2009038089A1 (en) Anti-fatigue agent comprising sesamin and vitamin-e
UA92803C2 (en) Treatment of trichostrongylus invasions of digestive tract of ruminants
WO2007009706A3 (en) Substituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
MD80Z (en) Method for prophylaxis and treatment of parasitoses in cattle

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09818255

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09818255

Country of ref document: EP

Kind code of ref document: A2